Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
401.01(c) 396.13(c) 410.99(c) 423.79(c) 427.64(c) Last
1 027 407 929 014 675 041 733 769 1 135 323 Volume
-3.71% -1.22% +3.75% +3.11% +0.91% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
02/19Earnings Release
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 791 M
EBIT 2014 1 142 M
Net income 2014 373 M
Finance 2014 1 084 M
Yield 2014 -
Sales 2015 3 435 M
EBIT 2015 1 620 M
Net income 2015 697 M
Finance 2015 2 163 M
Yield 2015 -
PER 2014 133,29
PER 2015 73,48
EV / Sales 2014 15,2x
EV / Sales 2015 12,0x
Capitalization 43 476 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
1d ago REGENERON PHARMACEUTICALS : Announces Presentation and Panel Discussion at the 3..
3d ago REGENERON PHARMACEUTICALS : "Methods for Treating Allergy and Enhancing Allergen..
5d ago REGENERON PHARMACEUTICALS : Have You Been Counted? Regeneron and Sanofi US Join ..
12/10 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Accepted for Priority R..
12/10 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/05 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/04 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Producing Hybrid Antibo..
12/03 REGENERON PHARMACEUTICALS : and Sanofi Announce that Dupilumab Has Received FDA ..
More news
Sector news
1h ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI
1d ago JAZZ PHARMACEUTICALS : Receives FDA Approval For Intravenous Administration Of E..
1d ago CUBIST PHARMACEUTICALS : FDA OKs Cubist antibiotic for serious infections
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF